|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Moreover, treatment with cimiracemate A attenuates the expression of receptor activator of nuclear factor kappa-Β ligand (RANKL), receptor activator of nuclear factor κ B (RANK), and osteoprotegerin (OPG) protein in glucocorticoid-induced osteoporosis rats.
|
30695776 |
2019 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this study, we report a siRNA delivery system consisting of PEI:RANK siRNA complex entrapped in nanosized poly(lactic acid-co-glycolic acid) (PLGA) capsules intended to be used in the treatment of osteoporosis.
|
29652606 |
2019 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been approved for osteoporosis treatment in adults.
|
31533771 |
2019 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
As an osteoclast differentiation factor, receptor activator of NF-κB ligand (RANKL) is produced by various immune cells and may be involved in the pathogenesis of osteoporosis and inflammation.
|
30737962 |
2019 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In summary, the rs3018362 polymorphism in the RANK gene seems to be associated with osteoporosis of the lumbar spine while the RANKL rs12585014 is not, although more studies are needed to confirm these results.
|
31126201 |
2019 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Vitamin C reduced the expression of osteoclast differentiation genes, such as receptor activator of nuclear factor kappa-B, receptor activator of nuclear factor kappa-B ligand, tartrate-resistant acid phosphatase, and cathepsin K. This study is the first to show that vitamin C can inhibit osteoporosis by promoting osteoblast formation and blocking osteoclastogenesis through the activation of wingless-type MMTV integration site family/β-catenin/activating transcription factor 4 signaling, which is achieved through the serine/threonine kinase and mitogen-activated protein kinase signaling pathways.
|
30818817 |
2019 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Denosumab (Dmab), a monoclonal antibody against the receptor activator of nuclear factor-κB (RANK) ligand (RANKL) which substantially suppresses osteoclast activity, has been approved for the treatment of common metabolic bone diseases, including postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis, in which the pathway of the RANK/RANKL/osteoprotegerin is dysregulated.
|
31454537 |
2019 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Denosumab inhibits the receptor activator of nuclear factor κB (RANK) pathway and is used to treat osteoporosis.
|
30420611 |
2018 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The protein-protein interactions between receptor activator of nuclear factor-κB ligand (RANKL), RANK (its receptor), and osteoprotegerin (OPG), are known to mediate the development and activation of osteoclasts in bone remodeling, and are regarded as a pivotal therapeutic target for the treatment of osteoporosis.
|
29348072 |
2018 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
To examine the effect of SNPs clustered within key pathways associated with the development of osteoporosis, subtype weighted GRS specific to WNT signaling (6 SNPs), RANK-RANKL-OPG (3 SNPs), and mesenchymal stem differentiation (3 SNPs) were generated for analysis.
|
29713799 |
2018 |
|
Osteoporosis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
TNF-α is highly correlated with the RANK and estrogen levels in PO patients. in vitro, TNF-α synergistically promotes RANKL-induced osteoclast formation by activation of NF-κB and PI3K/Akt signaling.
|
29571022 |
2018 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Reduced miR-144-3p expression in serum and bone mediates osteoporosis pathogenesis by targeting RANK.
|
29334613 |
2018 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Recent studies have revealed the importance and the active contribution of the RANKL/OPG/RANK pathway in many bone diseases including different forms of common osteoporosis.
|
28945380 |
2017 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.
|
29055350 |
2017 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Denosumab is a RANK-RANKL inhibitor, which is used to treat osteoporosis and bone GCT.
|
28454368 |
2017 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
RANK ligand (RANKL) is involved in destruction and osteoporosis in RA.
|
29029341 |
2017 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we aimed to evaluate the relationship between polymorphisms of the receptor activator of the nuclear factor kappa B (RANK) gene; the receptor activator of the nuclear factor kappa B ligand (RANKL) gene; and RANKL levels with osteoporosis in postmenopausal RA patients.
|
26914636 |
2016 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The RANK gene might contribute to genetic variability in L1-L4 BMD in postmenopausal Chinese women with osteoporosis or osteopenia.
|
26426211 |
2016 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Microcomputed tomography analysis demonstrated that the mice treated with rhRANK exhibited an increased bone volume and structure model index, and decreased trabecular spacing compared with those treated with rhOPG-Fc. rhRANK increased the inhibition of osteoclast differentiation and bone resorption, and rescued OVX-induced osteoporosis more effectively compared with rhOPG-Fc.
|
25738879 |
2015 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Negative correlations of total hip BMD with tumor necrosis factor-α (TNF-α) in OA and with RANKL/RANK in OP were found (p < 0.05).
|
22380539 |
2012 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In humans, dysregulation of the RANK-RANKL system is the major cause of osteoporosis in postmenopausal women.
|
21470874 |
2011 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the Avon longitudinal study of parents and children and gothenburg osteoporosis and obesity determinants cohorts.
|
20534768 |
2010 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In order to investigate the effects of RANK polymorphism on BMD and osteoporosis, we directly sequenced the RANK gene in 24 Korean individuals and identified 25 sequence variants.
|
17115234 |
2007 |
|
Osteoporosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The associations between BMP2 with UD BMD and those between RANK with OP at the spine, hip, and UD also met the experiment-wide stringent criterion (empirical global p < or = 0.0007).
|
17002564 |
2006 |
|
Osteoporosis
|
0.200 |
GeneticVariation
|
disease |
LHGDN |
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
|
15564564 |
2004 |